Key topics in HCC discussed at ASCO GI & EASL liver cancer summit 2022

Episode 1 • February 28, 2022 • 00:13:11
Key topics in HCC discussed at ASCO GI & EASL liver cancer summit 2022
COR2ED Medical Education
Key topics in HCC discussed at ASCO GI & EASL liver cancer summit 2022

Feb 28 2022 | 00:13:11

/

Show Notes

Medical Education podcast by COR2ED. Professor James Harding, HCC Connect member, provides his perspectives and insights on key abstracts and topics discussed at ASCO GI 2022 and EASL liver cancer summit 2022 in hepatocellular carcinoma. He discusses the HIMALAYA study which evaluated dual immune checkpoint blockade inhibition namely, anti-CTLA-4 antibody tremelimumab with the anti-PD-L1 antibody durvalumab in the frontline setting with patients with unresectable hepatocellular carcinoma. There were other important studies at the meeting and Prof Harding highlights the RENOBATE study and the GOING study that evaluated nivolumab in combination with regorafenib and early addition of nivolumab to regorafenib regimen, respectively.

Other Episodes

Episode

November 21, 2023 • 00:29:54
Episode Cover

Prostate Cancer: Pre-Analytical Phase Challenges and Biomarker Testing

What are the common pre-analytical phase challenges in prostate cancer, and how can we overcome them? Why is it important to identify genetic alterations?...

Listen

Episode 1

July 28, 2022 • 00:22:00
Episode Cover

Prostate Cancer Highlights from ASCO GU, ASCO and EAUN 2022

Prostate Cancer Highlights from ASCO GU, ASCO and EAUN 2022 COR2ED Medical Education: In this podcast Dr Jason Alcorn and Jennifer Sutton discuss the...

Listen

Episode 12

April 26, 2023 • 00:21:09
Episode Cover

Treatment sequencing in advanced mCRC patients

COR2ED Medical Education: This podcast episode discusses treatment sequencing in advanced metastatic colorectal cancer (mCRC) patients, third line and beyond.  Dr Shubham Pant from...

Listen